Concepedia

G Weil-Hillman

GW

Statistics

Publications

12

Citations

491

H-Index

12

Active since

1985

Affiliations

University of Wisconsin–Madison(Current)

Radiation Oncology Associates

G Weil-Hillman is an author at University of Wisconsin–Madison specializing in immunology, life sciences, and cancer immunology.

Publications per year

1985–1991

12

Publications

12

Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.

G Weil-Hillman, Paul Fisch, Audrey F. Prieve et al. · PubMed · 1989 · 85 citations

Life Sciences, Immunology, Oncology +12

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

J A Hank, Peter Köhler, G Weil-Hillman et al. · PubMed · 1988 · 81 citations

Life Sciences, Immunology, Oncology +15

The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment.

Stephan D. Voss, G Weil-Hillman, Jacquelyn A. Hank et al. · PubMed · 1989 · 62 citations

Medicine, Immunology, Oncology +16

Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.

Stephan D. Voss, R J Robb, G Weil-Hillman et al. · The Journal of Experimental Medicine · 1990 · 53 citations · Full text

Life Sciences, Cell Biology, Immunology +16

Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.

G Weil-Hillman, Walter Runge, F. K. Jansen et al. · PubMed · 1985 · 37 citations

Medicine, Immunology, Oncology +15

1–5 of 12